MUC1-C是来那度胺耐药多发性骨髓瘤的靶点
来那度胺通过 cereblon 介导降解 IKZF1/IKZF3 直接作用于多发性骨髓瘤细胞,MUC1-C 癌蛋白在骨髓瘤细胞异常表达并保护其免受活性氧介导的死亡。本研究显示 MUC1-C 抑制剂 GO-203 与来那度胺联合在下调 WNT/β-catenin、抑制 MYC 和诱导晚期凋亡/坏死上超过相加效应,并可增敏来那度胺耐药细胞。
要点
- GO-203抑制MUC1-C同二聚化,与来那度胺联合在骨髓瘤细胞中产生超过相加的效应。
- GO-203可作用于来那度胺耐药骨髓瘤细胞,并使其对来那度胺重新敏感。
- 靶向MUC1-C下调原代骨髓瘤细胞表面CD44,MUC1与CD44表达在原代骨髓瘤细胞微阵列中显著相关。
核心结论
- 靶向MUC1-C可作用于来那度胺耐药多发性骨髓瘤细胞,并使其对来那度胺重新敏感。
- GO-203与来那度胺联合为多发性骨髓瘤及来那度胺耐药的治疗提供了支持。
研究设计与样本
- 本研究为体外研究,使用细胞穿透肽GO-203靶向MUC1-C,并在多发性骨髓瘤细胞及原代骨髓瘤细胞中评估与来那度胺的联合效应。
主要发现
- GO-203与来那度胺联合在下调WNT/β-catenin通路、抑制MYC和诱导晚期凋亡/坏死方面超过相加效应。
- GO-203与来那度胺联合通过协同增加活性氧进而抑制β-catenin发挥作用。
- 靶向MUC1-C对来那度胺耐药骨髓瘤细胞有效。
- GO-203使来那度胺耐药骨髓瘤细胞对来那度胺重新敏感,并伴随β-catenin和CD44的抑制。
- 靶向MUC1-C下调原代骨髓瘤细胞表面的CD44。
关键数值与推荐
- 原代骨髓瘤细胞微阵列中MUC1与CD44表达显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide (LEN) acts directly on multiple myeloma (MM) cells by inducing cereblon-mediated degradation of interferon regulatory factor 4, Ikaros (IKZF)1 and IKZF3, transcription factors that are essential for MM cell survival. The mucin 1 (MUC1) C-terminal transmembrane subunit (MUC1-C) oncoprotein is aberrantly expressed by MM cells and protects against reactive oxygen species (ROS)-mediated MM cell death. The present studies demonstrate that targeting MUC1-C with GO-203, a cell-penetrating peptide inhibitor of MUC1-C homodimerization, is more than additive with LEN in downregulating the WNT/β-catenin pathway, suppressing MYC, and inducing late apoptosis/necrosis. We show that the GO-203/LEN combination acts by synergistically increasing ROS and, in turn, suppressing β-catenin. LEN resistance has been linked to activation of the WNT/β-catenin→CD44 pathway. In this regard, our results further demonstrate that targeting MUC1-C is effective against LEN-resistant MM cells. Moreover, GO-203 resensitized LEN-resistant MM cells to LEN treatment in association with suppression of β-catenin and CD44. Targeting MUC1-C also resulted in downregulation of CD44 on the surface of primary MM cells. These findings, and the demonstration that expression of MUC1 and CD44 significantly correlate in microarrays from primary MM cells, provide support for combining GO-203 with LEN in the treatment of MM and in LEN-resistance.
引用
- Yin L, Tagde A, Gali R, et al. MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017. PMID: 28643330. doi:10.1111/bjh.14801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。